Aspirin and multiple sclerosis

Area of Science:

• Neuroscience
• Pharmacology
• Cardiovascular Medicine

Background:

• Multiple sclerosis (MS) patients exhibit increased risk for cardiovascular events like venous thromboembolism and ischemic strokes.
• Aspirin is a common medication for cardiovascular event prevention.
• The potential benefits and risks of aspirin in MS patients are not fully understood.

Purpose of the Study:

• To evaluate the potential benefits of aspirin in mitigating cardiovascular risks for multiple sclerosis patients.
• To explore aspirin's potential role in addressing MS-specific pathological mechanisms, such as inflammation and remyelination.
• To assess the risks associated with aspirin use in multiple sclerosis, including hemorrhagic stroke and mitochondrial function.

Main Methods:

• Review of existing studies on aspirin's cardiovascular effects.
• Analysis of research on aspirin's impact on inflammation and mitochondrial function.
• Examination of experimental data on aspirin's effect on oligodendrocyte precursor cells.

Main Results:

• Aspirin may reduce cardiovascular risks in MS patients, particularly in subgroups with limited mobility or antiphospholipid antibodies.
• Aspirin demonstrated potential in experimental models to promote remyelination by affecting oligodendrocyte precursors.
• Concerns exist regarding aspirin's increased risk of hemorrhagic stroke and potential inhibition of mitochondrial complex I activity, which is already impaired in MS.

Conclusions:

• Aspirin presents a complex risk-benefit profile for multiple sclerosis patients.
• Further research is warranted to determine optimal use cases and safety in specific MS populations.
• Aspirin's potential to reduce cardiovascular events and aid remyelination must be weighed against its associated risks.